Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Mott

Showing results (81-90 of 113) with videos related to

Pageof 12
Sort By:
Bioorganic & Medicinal Chemistry Letters|October 20, 2009
Evaluation of substituted 6-arylquinazolin-4-amines as potent and selective inhibitors of cdc2-like kinases (Clk)Bryan T Mott, Cordelle Tanega, Min Shen, et al.
Journal of Neuropathology and Experimental Neurology|May 17, 2005
Neuropathologic, biochemical, and molecular characterization of the frontotemporal dementiasRyan T Mott, Dennis W Dickson, John Q Trojanowski, et al.
Blood Advances|February 9, 2021
Antileukemic efficacy of a potent artemisinin combined with sorafenib and venetoclaxBlake S Moses, Samantha McCullough, Jennifer M Fox, et al.
Journal of Neuro-Oncology|February 24, 2012
Patterns of failure after treatment of atypical meningioma with gamma knife radiosurgeryAlbert Attia, Michael D Chan, Ryan T Mott, et al.
Oncotarget|January 16, 2016
Artemisinin-derived dimer ART-838 potently inhibited human acute leukemias, persisted in vivo, and synergized with antileukemic drugsJennifer M Fox, James R Moynihan, Bryan T Mott, et al.
Scientific Reports|November 25, 2016
mQC: A Heuristic Quality-Control Metric for High-Throughput Drug Combination ScreeningLu Chen, Kelli Wilson, Ian Goldlust, et al.
Oncogene|April 17, 2022
Targeting oncometabolism to maximize immunotherapy in malignant brain tumorsJoshua D Bernstock, Kyung-Don Kang, Neil V Klinger, et al.
Medchemcomm|December 4, 2012
A furoxan-amodiaquine hybrid as a potential therapeutic for three parasitic diseases()Bryan T Mott, Ken Chih-Chien Cheng, Rajarshi Guha, et al.
Cancers|March 28, 2020
Inhibiting WNT Ligand Production for Improved Immune Recognition in the Ovarian Tumor MicroenvironmentWhitney N Goldsberry, Selene Meza-Perez, Angelina I Londoño, et al.
Chemmedchem|February 8, 2014
A cell-permeable ester derivative of the JmjC histone demethylase inhibitor IOX1Rachel Schiller, Giuseppe Scozzafava, Anthony Tumber, et al.
Pageof 12

Showing results (81-90 of 113) with videos related to

Sort By:
Pageof 12
Bioorganic & Medicinal Chemistry Letters|October 20, 2009
Evaluation of substituted 6-arylquinazolin-4-amines as potent and selective inhibitors of cdc2-like kinases (Clk)Bryan T Mott, Cordelle Tanega, Min Shen, et al.
Journal of Neuropathology and Experimental Neurology|May 17, 2005
Neuropathologic, biochemical, and molecular characterization of the frontotemporal dementiasRyan T Mott, Dennis W Dickson, John Q Trojanowski, et al.
Blood Advances|February 9, 2021
Antileukemic efficacy of a potent artemisinin combined with sorafenib and venetoclaxBlake S Moses, Samantha McCullough, Jennifer M Fox, et al.
Journal of Neuro-Oncology|February 24, 2012
Patterns of failure after treatment of atypical meningioma with gamma knife radiosurgeryAlbert Attia, Michael D Chan, Ryan T Mott, et al.
Oncotarget|January 16, 2016
Artemisinin-derived dimer ART-838 potently inhibited human acute leukemias, persisted in vivo, and synergized with antileukemic drugsJennifer M Fox, James R Moynihan, Bryan T Mott, et al.
Scientific Reports|November 25, 2016
mQC: A Heuristic Quality-Control Metric for High-Throughput Drug Combination ScreeningLu Chen, Kelli Wilson, Ian Goldlust, et al.
Oncogene|April 17, 2022
Targeting oncometabolism to maximize immunotherapy in malignant brain tumorsJoshua D Bernstock, Kyung-Don Kang, Neil V Klinger, et al.
Medchemcomm|December 4, 2012
A furoxan-amodiaquine hybrid as a potential therapeutic for three parasitic diseases()Bryan T Mott, Ken Chih-Chien Cheng, Rajarshi Guha, et al.
Cancers|March 28, 2020
Inhibiting WNT Ligand Production for Improved Immune Recognition in the Ovarian Tumor MicroenvironmentWhitney N Goldsberry, Selene Meza-Perez, Angelina I Londoño, et al.
Chemmedchem|February 8, 2014
A cell-permeable ester derivative of the JmjC histone demethylase inhibitor IOX1Rachel Schiller, Giuseppe Scozzafava, Anthony Tumber, et al.
Pageof 12